VRDN SCHEDULE 13G: SEC filing
Filed with the SEC on · accession 0000919574-26-005637
VRDN filed a SCHEDULE 13G (schedule 13g) with the SEC on Aug 20, 2026. Point72 Asset Management, Point72 Capital Advisors, and Steven A. The stock moved -1.2% by the first close after the filing.
Summary of the filing
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen filed a joint Schedule 13G regarding their ownership position in Viridian Therapeutics. The filing is a passive ownership disclosure with no stated intent to influence control.
Key details
How VRDN stock reacted
Close before
$24.80
Aug 19, 2026
First close after
-1.21%
$24.50
5 trading days
-2.18%
$24.26
Since filing
+15.12%
$28.55
✦ Ask GOAX AI about this filing — what it means for VRDN, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for VRDN?
Click hereFrequently asked questions
What did VRDN file with the SEC on Aug 20, 2026?
VRDN filed a SCHEDULE 13G (SEC filing). Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen filed a joint Schedule 13G regarding their ownership position in Viridian Therapeutics. The filing is a passive ownership disclosure with no stated intent to influence control.
How do I read a SCHEDULE 13G?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).
How did VRDN stock react to this filing?
VRDN closed at $24.80 before the filing and $24.50 on Aug 20, 2026 (-1.21%). Five trading days later: $24.26 (-2.18%).
Other VRDN SEC filings
- 10-Q · SEC filingNov 4, 2026
- 8-K · SEC filingNov 4, 2026
- 10-Q · Material agreementAug 6, 2026
- 8-K · Guidance raiseAug 6, 2026
- 8-K · Fda approvalJun 29, 2026
- 8-K · Board changeJun 3, 2026
- 8-K · SEC filingMay 28, 2026
- 8-K · Material agreementMay 26, 2026
- 8-K · Secondary offeringMay 11, 2026
- 424B5 · Secondary offeringMay 8, 2026
Get alerts when VRDN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days